

A European regulatory perspective

Eva Gil Berglund Senior Expert, PhD Medical Products Agency Sweden



The views expressed in this presentation are mine and may not represent those of either EMA, the PKWP, or MPA





approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • environment • evaluation • approvals • authorisation • clinical trials • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • parcotics • public health



21 June 2012 CPMP/EWP/560/95/Rev. 1 Corr. 2** Committee for Human Medicinal Products (CHMP)

Guideline on the investigation of drug interactions

Adopted Coming into effect June 2012 January 2013



approvais autionisation clinical trais communication competence cosmics dialogue arectives enlicacy environment evaluation guidelines narmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal oroducts • medical devices • approvals • authorisation

Transporter highlights in the guideline

- Recommend identifying transporters important for absorption and elimination in vivo and performing relevant DDI studies.
- Published a living list of transporters for which inhibition should be screened
- and cut-offs for in vivo relevance of in vitro inhibition signals based on available data (Pgp) or estimations from the enzyme experience
- Provide recommendations on in vitro study design



approvals • authorisation • clinical trais • communication • competence • cosmics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • public health •

Initial issues in applications

- Transporters not identified although there was significant metabolism (OATPs) or biliary excretion
- Problems interpreting mass-balance data and worst-case thinking (without iv data)
- Lack of in vivo DDI or PGx studies
- Lack of justification of chosen in vitro system and probe drug / inhibitor
- Too high concentrations in substrate assays
- DDI risk/study with inducer in vivo not considered
- Stability, adsorption in assays
- Controls in in vitro study (inhibitors, untransfected cells, etc)




approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • communication • competence • cosmics • dialogue • directives • efficacy • environment • evaluation • particulation • health economics · herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • public health

Initial issues

- ---- almost solved solved
- Transporters not identified although there is significant metabolism (OATPs) or biliary excretion
- Problems interpreting mass-balance data and worstcase thinking (without iv data)
- Lack of in-vivo DDt or PGx studies-
- Justify in vitro system and probe drug / inhibitor
- Too high concentrations in substrate assays
- DDI risk/study with inducer in vivo not considered
- -Stability,-adsorption-in assays
- Controls in in vitro study (inhibitors, untransfected cells, etc)

The applications have markedly improved!

The guideline was applied more flexibly in the beginning.



We are also learning with the applications



approvals autinonisation • clinical trais • communication • competence • cosmitos • dialogue • cirectives • efficacy • environment • evaluation • guidelines • narmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • autoris

Missing information in today's applications

- Caco-2 cell studies with inhibited/saturated transporters, controls
- Double systems for inhibition of Pgp
- Justify in vitro system and probe drug / inhibitor
- Justify using EC₅₀ (time and conc. independent)
- DDI risk/study with inducer in vivo not considered
- Use dabigatran etexilate instead of digoxin for intestinal Pgp inhibition
- i.v data (bioavailability) supporting estimation of biliary excretion from mass-balance data
- PGx, stratified studies




approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • public health • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • public health

Additional knowledge: rate limiting step

- The uptake to the hepatocyte may be rate limiting for the elimination
- Inhibition of a major metabolism pathway may not affect drug exposure, only metabolite exposure – parent drug may be misleading in elimination investigations.
- Useful to check metabolites!
- In vitro metabolite formation data important.
- (The effect of inhibition of uptake transport is not influenced by these considerations. Inhibition will always have an effect on elimination ruled by its contribution as compared to passive permeation.)

See Maeda et al, CPT 2011






Time for more data and less text

Illustrative data in recent submissions



approvals autononsation • clinical trais • communication • competence • cosmitos • dialogue • cirectives • efficacy • environment • evaluation • guidelines • narmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation clinical trials • communication • competence • cosmetics • dialogue • directives • environment • evaluation • approvals • authorisation • herbals • homeonathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • approvals • authorisation


Discussed last week - Importance of i.v. data





approvals = authorisation = clinical trials = communication = competence = cosmitics = dialogue = clirectives = etilicacy = environment = evaluation = guidelines = narmonisation = health economics = herbals = homeopathics = information = inspection laboratory analysis = market surveillance = medicinal products = medical devices = narcotics = public health = guality = registration = regulations = reliability = risk/benefit = safety = scientific = standardisation = transparency = vigilance = approvals = authorisation = clinical trials = communication = competence = cosmetics = dialogue = directives = efficacy = environment = evaluation = approvals = authorisation = clinical trials = communication = competence = cosmetics = dialogue = directives = efficacy = environment = evaluation = approvals = authorisation = herbals = homeopathics = information = inspection laboratory analysis = market surveillance = medicinal products = medicinal products = narcotics = public health = public health = communication = cosmetics = public health = standardisation = cosmetics = public health = communication = cosmetics = dialogue = directives = efficacy = environment = evaluation = approvals = authorisation = herbals = homeopathics = information = inspection laboratory analysis = market surveillance = medicinal products = medicinal evolution = cosmetics = public health = cosmetics = co

Supportive data



Food interaction (other formulation) rather high on other formulation indicating a quite low Fabs.



Dabigatran vs digoxin

Drug X/Y, Pgp/BCRP inhibitor in intestine

Dabigatran

150 mg, caps

Cmax 105%↑ AUC 138%↑ t1/2 9,9 to 13 hrs

Digoxin

fed

0.5 mg, tablet fed

Cmax 72%↑ AUC 48%↑ t1/2 37 to 42hrs CLR ↔


Why making a (sensitive) in vivo study?

Support labelling of intestinal Pgp


substrates: dabigatran, sofosbuvir, tenofovir alafenamide, coming NCEs (digoxin TDM)



approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality • registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • hereithe • conomics • hereithe • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • hereithe • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • hereithe • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • hereithe • cosmetics • evaluation • evaluation • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • evaluation • hereithe • cosmetics • evaluation • evaluation • competence • cosmetics • evaluation • evaluation • evaluation • evaluation • evaluation • evaluation • eva



Remember DDIs with inducers on drugs with significant intestinal Pgp/BCRP transport





approvals • autriorisation • cinical trais • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • guidelines • narmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trais • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • guidelines • harclinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmitos • dialogue • directives • environment • evaluation • guidelines • harmonisation • competence • cosmitos • dialogue • directives • environment • evaluation • guidelines • harmonisation • competence • cosmitos • dialogue • directives • environment • evaluation • guidelines • harmonisation • competence • cosmitos • dialogue • directives • environment • evaluation • guidelines • harmonisation • competence • cosmitos • public • directives • parcotice • parcotice • public • directives • parcotice • public • directives • approval • approval • approval • approval • approval • approval • approva

Other examples: Inducers on intestinal Pgp

- Dabigatran RIF: AUC \downarrow by 67 %.
- Drug X RIF: Cmax \downarrow by 79%, AUC \downarrow by 87%
- TAF efavirenz: Cmax ↓ by 22%, AUC ↓ by 14% (No RIF study, labelled "Not recommended")
- (Digoxin RIF staggered Cmax ↓ by 22%, AUC ↓ by 19%, CLR ↔ (other transporter inhibited))

Kirby et al DMD 2012



approvals * authonisation * clinical trais * communication * competence * cosmitos * dialogue * directives * efficacy * environment * evaluation * guidelines * narmonisation * health economics * herbals * homeopathics * information * inspection laboratory analysis * market surveillance * medicinal products * medical devices * narcotics * public health * quality registration * regulations * reliability * risk/benefit * safety * scientific * standardisation * transparency * vigilance * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * evaluation * bealth * evaluation * approval * approval * authorisation * inspection laboratory analysis * market surveillance * medicinal products * medical devices * arcotics * public health



Assessment time

Some recent questions



approvals * authonisation • clinical trais • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trais • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • guidelines • harclinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • environment • evaluation • guidelines • harmonisation • clinical trials • communication • competence • cosmetics • dialogue • directives • environment • evaluation • guidelines • harmonisation • clinical trials • communication • competence • cosmetics • dialogue • directives • environment • evaluation • guidelines • harmonisation • clinical trials • communication • competence • cosmetics • dialogue • directives • environment • evaluation • guidelines • harmonisation • health • conomics We look a lot on the half-lives in DDI studies trying to get information on the site of the DDI (intestine or liver).


Why is the half-life sometimes unchanged by OATP1B1/3 inhibition?



approvals • authorisation • clinical trials • communication • competence • cosmtics • dialogue • directives • efficacy • environment • evaluation • guidelines • harmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality • registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • clinical trials • tormenonathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • parconsitios • parcentics • parcentics

OATP inhibition and t_{1/2}

Rifampicin single dose on drug Y (OATP1B1/3, BCRP/Pgp substrate, fu 2.7%, Vd?) AUC 8.55-fold \uparrow t_{1/2} \downarrow from 5.70 to 3.80 hrs Effect also on Vd?



CyA gave AUC 8.5-fold \uparrow and $t_{1/2} \uparrow$ fr. 5.5 to 11.4 hrs and Darunavir/r 800/100 qd gave AUC 5-fold \uparrow and $C_{trough} \uparrow$ 8-fold Lopinavir/r 400/100 bid gave AUC 4.4-fold \uparrow and $C_{trough} \uparrow$ 19-fold Atazanavir/r 300/100 qd gave gave AUC 6.5-fold \uparrow and $C_{trough} \uparrow$ 14-fold




pprovals • authorsation • clinical trais • communication • competence • cosmitics • dialogue • directives • efficacy • environment • evaluation • guidelines • hartonisation • health • controls • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices narcotics • public health • quality • registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • uthorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • uthorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • partices • authorisation • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • public health •

Effect by OATP1B1/3, Pgp and BCRP inhibitory combination Losartan

50% biliary elimination, OATP1B1/3 substrate, Vd 17L, low fu Valsartan

biliary excretion main pathway, OATP substrate, Vd 34L, low fu

Losartan AUC 1.56, t1/2 2.1 to 0.9hrs Valsartan AUC 1.31, t1/2 8.9 to 5.9






approvals & autoonisation • clinical trais • communication • competence • cosmitos • dialogue • orrectives • efficacy • environment • evaluation • guidelines • narmonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market survelllance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • elinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • elinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • health • evaluation • health • conomics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • public health •

How are the hepatocyte concentrations affected?

By induction?

By inhibition of the efflux transporters?



Can we do anything to know more? (Post-marketing follow up, KO, etc)

ITC paper 2010



approvals automisation clinical trials communication competence cosmics dialogue clinectives enlicacy environment evaluation guidelines narmonisation e health economics e herbals e homeopathics e information e inspection laboratory analysis e market surveillance e medicinal products e medical devices e narcotics e public health e quality registration e regulations e reliability e risk/benefit e safety e scientific e standardisation e transparency e vigilance e approvals e authorisation e clinical trials e communication e competence e cosmetics e dialogue e directives efficacy environment evaluation e approvals e authorisation clinical trials e communication e competence e cosmetics e dialogue e directives efficacy environment evaluation e approvals e authorisation e clinical trials e communication e competence e cosmetics e dialogue e directives efficacy environment evaluation e approvals e authorisation e herbals e homeopathics e information e inspection laboratory analysis e market surveillance e medicinal products e medical devices e approvals e authorisation

Up, down, tox or what?



 Difficult to extrapolate DDI effects to other scenarios when multiple transporters involved.

Identified for HIV drugs in the DDI guideline :

... most drug-drug interaction can be predicted. However, it is acknowledged that there are remaining scientific uncertainties. In the area of HIV there have been cases of unexpected interactions. When developing a drug in such an area, *in vivo* interaction studies should be considered with commonly combined drugs having a relatively narrow therapeutic window while more knowledge is gained on the mechanism behind the unsuspected interactions in the field.

This can be applied to other fields/situations with complex DDI mechanisms, especially involving transporters.



Time for a guideline update

PKWP workplan 2017 EU Guidelines under revision

UPDATE ALERTI Guideline on the investigation of drug interactions, EMEA/CHMP/EWP/147013/2004

Target date

Concept paper to be released for public consultation Q1 2017 Under preparation for publication.



Not a major update but Proposed changes includes

- Specific recommendations for in vitro studies on
 - o **Transport**
 - o TDI
 - o Induction
- Update of transporter list (for inhibition screening)
- Update on cut-offs for transporter inhibition
- Transport as rate limiting step
- Clarifications of guideline text
- Discussion of DDI study requirement with contraceptive steroids



approvals * authorisation * clinical trials * communication * competence * cosmtics * dialogue * directives * efficacy * environment * evaluation * guidelines * harmonisation * health economics * herbals * homeopathics * information * inspection laboratory analysis * market surveillance * medicinal products * medical devices * narcotics * public health * quality * registration * regulations * reliability * risk/benefit * safety * scientific * standardisation * transparency * vigilance * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * herbals * homeopathics * information * inspection laboratory analysis * market surveillance * medicinal products * medical devices * public health

Public consultation

- Q1 2017 aimed for publication at 1st of April
- 3 months consultation period





approvals * autonisation * clinical trais * communication * competence * cosmitos * otalogue * orrectives * etilicacy * environment * evaluation * guidelines * narmonisation * health economics * herbals * homeopathics * information * inspection laboratory analysis * market surveillance * medicinal products * medical devices * narcotics * public health * quality registration * regulations * reliability * risk/benefit * safety * scientific * standardisation * transparency * vigilance * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * directives * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * dialogue * efficacy * environment * evaluation * approvals * authorisation * clinical trials * communication * competence * cosmetics * efficacy * environment * evaluation * evaluation * bealth * evaluation * approval * authorisation * inspection laboratory analysis * market surveillance * medicinal oroducts * medical devices * arcotics * public health

Thank you for listening!



Are there any clarifying questions?



approvals • authorisation • clinical frials • communication • competence • cosmitos • dialogue • directives • efficacy • environment • evaluation • guidelines • harnonisation • health economics • herbals • homeopathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health • quality• registration • regulations • reliability • risk/benefit • safety • scientific • standardisation • transparency • vigilance • approvals • authorisation • clinical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • communication • competence • cosmetics • dialogue • directives • efficacy • environment • evaluation • approvals • authorisation • linical trials • homeonathics • information • inspection laboratory analysis • market surveillance • medicinal products • medical devices • narcotics • public health